Navigation Links
Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
Date:6/3/2011

privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. The company's unique approach to targeting cancer metabolism has led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated. Its lead drug, CPI-613, is currently being evaluated in three ongoing Phase I and Phase I/II clinical trials in a variety of tumor types.

About Wake Forest Baptist Medical Center

Wake Forest Baptist Medical Center (www.wakehealth.edu) is a fully integrated academic medical center located in Winston-Salem, N.C. Wake Forest School of Medicine directs the education and research components, with the medical school ranked among the nation's best and recognized as a leading research center in regenerative medicine, cancer, the neurosciences, aging, addiction and public health sciences. Piedmont Triad Research Park, a division of Wake Forest Baptist, fosters biotechnology innovation in an urban park community. Wake Forest Baptist Health, the clinical enterprise, includes a flagship tertiary care hospital for adults, Brenner Children's Hospital, a network of affiliated community-based hospitals, physician practices and outpatient services. The institution's clinical programs and the medical school are consistently recognized as among the best in the country by U.S.News & World Report.

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticip
'/>"/>

SOURCE Cornerstone Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
5. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
8. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
9. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
10. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
11. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... to present a corporate overview and update at the Piper ... 2, 2014, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific ... New York . A live audio webcast ... section of Arena,s website at www.arenapharm.com . A replay ...
(Date:11/24/2014)... 24, 2014 Luoxis Diagnostics, Inc., a ... today announced the presentation of three clinical and ... a broadly applicable and robust research tool capable ... in response to injury, illness, or stress.  In ... with Luoxis, academic and pharmaceutical research partners, RedoxSYS ...
(Date:11/24/2014)... The Female Health Company (NASDAQ-CM: FHCO), today ... to discuss its operating results for the fourth quarter ... December 2, 2014 at 11:00 a.m. Eastern Standard Time ... earlier the same day. Shareholders and other ... dialing 1-877-374-8416 (international participants dial 1-412-317-6716) and asking to ...
Breaking Medicine Technology:Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2
... SAN FRANCISCO, Calif., May 16, 2011 diaDexus, Inc. (OTC ... on the development and commercialization of patent-protected in vitro ... announced financial results for the first quarter of 2011. ... were $3.3 million, representing 25% growth over total revenues of ...
... Oncology molecules in development will be presented during the 47th ... held in Chicago, Ill. from June 3 – 7, 2011. ... industry, with more than 30 molecules in development to treat ... these pipeline molecules are being evaluated for certain biomarkers or ...
Cached Medicine Technology:diaDexus, Inc. Reports 2011 First Quarter Financial Results 2diaDexus, Inc. Reports 2011 First Quarter Financial Results 3diaDexus, Inc. Reports 2011 First Quarter Financial Results 4diaDexus, Inc. Reports 2011 First Quarter Financial Results 5Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011 2Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011 3
(Date:11/24/2014)... SafeHandles™ announced that they will be ... Begley Jr, airing via Discovery Channel. Dates and show ... passive, non-invasive, replaceable, and affordable germ protective device. This ... sleeves and adhesives to promote hand hygiene in high ... of SafeHandles is the desire to make a positive ...
(Date:11/24/2014)... 24, 2014 "My friend was killed ... to cross the street in his motorized wheelchair," said ... him. I came up with this idea so that ... , He developed the Safety Lites to make a ... conditions. The device ensures that motorists can see the ...
(Date:11/23/2014)... November 23, 2014 The report, ... 2006 to 2020 - Asia-Pacific” provides quantitative analysis ... market segments: minimally invasive body contouring devices, non-invasive ... analysis includes market size data by revenue and ... following countries: China, Japan, South Korea, Australia and ...
(Date:11/23/2014)... friends have more influence on teens, alcohol use than ... "We,ve known for a long time that ... use, but there are no common studies that distinguished ... influence on those decisions," Jonathon Beckmeyer, an assistant professor ... a university news release. Beckmeyer analyzed data gathered ...
(Date:11/23/2014)... show thanks to new and old customers, iFitDress.com has ... for weddings. Customers who need custom outfits can talk ... dress manufacturer, and it is among the ones which have ... long time. The CEO of this company says, "iFitDress.com is ... buy not only a beautiful dress, but also a piece ...
Breaking Medicine News(10 mins):Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Close Friends May Be Key to Teens' Drinking 2Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2
... Demonstrates a 20-Meter Improvement in Six-Minute Walk ... Distance ... Time on November 1, 2007, SILVER SPRING, Md., Nov. 1 ... Rx, Inc., announced today the completion of their TRIUMPH-1 Phase 3,trial ...
... Calif., and WHITEHOUSE STATION, N.J., Nov. 1, Dynavax ... Co., Inc. (NYSE: MRK ) today announced ... develop HEPLISAV(TM), a,novel investigational hepatitis B vaccine, which ... clinical trial involving adults and in,patients on dialysis. ...
... 1 The makers of the WaveSense line ... Claudio,Carboni, formerly of Menarini Diagnostics, has joined as ... WaveSense Europe will,distribute the company,s high accuracy, WaveSense ... market both directly and through local,partners. Carboni ...
... Upload Video Confessions/ Testimonials for ... PHILADELPHIA and LONDON, Nov. 1 Thomson,Scientific, ... ; TSX: TOC) and,leading provider of information solutions ... the launch of its new campaign,"Confessions ... of ...
... (MHS), a not-for-profit health care system with hospitals ... it has selected,Integrated Healthcare Holdings, Inc. (IHHI) to ... partially physician-owned publicly traded hospital management,company, owns and ... total of,770 beds, 2787 employees and 1725 active ...
... Oct. 31 Always Best Care Senior,Services has expanded ... Living Placement Service, and Personal Response Company, is,proud to ... Always Best Care,Senior Services for outstanding care. For over ... our work - a sincere concern for,the betterment of ...
Cached Medicine News:Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 2Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 3Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 4Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 5Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 6Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 2Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 3Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 4Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 5Health News:Ex-Head of Menarini Diabetes Unit Launches WaveSense Europe 2Health News:Thomson Scientific Launches 'Confessions ... of a User' Campaign Asking 'Are You the New Face of Research?' 2Health News:Memorial Health Services Announces Sale of Anaheim Memorial Medical Center 2Health News:Announcing Always Best Care Senior Services Expansion Into San Diego, California 2
... smallest handheld oximeters available, Datex-Ohmeda s TuffSat ... home care, transport, and EMS. TuffSat comes ... (relative perfusion index measurement) a quick, ... reflection of perfusion at the sensor site. ...
... the power of clinical information. , ... of clinical connectivity solutions that help you ... high-quality patient care. You will have access ... to share it with your care team ...
... For safe and easy patient monitoring during MRI, ... the special needs of the MRI environment. It ... during MRI, promoting safety and flexibility., ,Though ... offers all the key benefits of the S/5 ...
... Compact and comprehensive solution for ... Arrhythmia Workstation (ARRWS) provides one compact, ... telemetry monitored patients. It connects to ... analysis for up to 16 beds., ...
Medicine Products: